TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development
J. Clin. Invest. Anne Grosse-Wilde, et al. 118:100 doi:10.1172/JCI33061 [Go to this article.]

Figure 3
TRAIL-R suppresses lymph node metastases of skin carcinomas. (A) Time course of detection of metastatic lymph nodes per total mice in study analyzed (left panel). Significantly higher incidence of lymph node metastases in TRAIL-R–deficient mice compared with TRAIL-R–expressing mice was detected upon necropsy (right panel), as determined by Pearson χ² test. (B–E) Tissue sections were stained with H&E and a keratin-specific antibody. Lymph nodes of Trail-r^–/– mice with keratin-positive metastatic lesions with SCC morphology (B, D, and E) or keratin-negative metastatic lesions (met) with fibrosarcoma (FSA) morphology (C). All stainings shown were from specimens obtained from tumors of Trail-r^–/– mice.